Cargando…

Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations

Detalles Bibliográficos
Autores principales:	Stoliaroff-Pepin, Anna, Harder, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2023
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101758/ https://www.ncbi.nlm.nih.gov/pubmed/37062303 http://dx.doi.org/10.1016/S1473-3099(23)00187-1

Ejemplares similares

Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
por: Vasin, Andrey V, et al.
Publicado: (2023)

Effectiveness of mRNA booster doses against the omicron variant
por: Zedan, Hadeel T, et al.
Publicado: (2022)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

What a second booster dose of mRNA COVID-19 vaccines tells us
por: Loubet, Paul, et al.
Publicado: (2022)

Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters
por: Lasrado, Ninaad, et al.
Publicado: (2023)

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
por: Ligumsky, Hagai, et al.
Publicado: (2022)

Immunologic Effect of Bivalent mRNA Booster in Patients Undergoing Hemodialysis
por: Huth, Luca, et al.
Publicado: (2023)

Mixing mRNA, adenoviral, and spike-adjuvant vaccines for protection against COVID-19
por: Richardson, Christopher D
Publicado: (2022)

Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study
por: Andersson, Niklas Worm, et al.
Publicado: (2023)

Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022
por: Huiberts, Anne J, et al.
Publicado: (2023)

COVID-19 mRNA vaccination and myocarditis or pericarditis
por: Husby, Anders, et al.
Publicado: (2022)

Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster
por: Davis-Gardner, Meredith E., et al.
Publicado: (2022)

Serum Neutralization of Omicron XBB.1.5 in Kidney Transplant Recipients After Bivalent mRNA Booster Vaccination
por: Pedersen, Rune M., et al.
Publicado: (2023)

Safety of mRNA COVID-19 vaccines during pregnancy
por: Ellington, Sascha, et al.
Publicado: (2022)

Acute tolerance of Moderna mRNA-1273 vaccine against COVID-19 in patients with cancer treated with radiotherapy
por: Scoccianti, Silvia, et al.
Publicado: (2021)

Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants
por: Li, Jianglong, et al.
Publicado: (2022)

Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients
por: Solera, Javier T, et al.
Publicado: (2023)

Impact of methotrexate on first-dose COVID-19 mRNA vaccination
por: Connolly, Caoilfhionn M, et al.
Publicado: (2021)

Recovery from mRNA COVID-19 vaccine-related myocarditis
por: Ammirati, Enrico, et al.
Publicado: (2022)

Adult-onset Still's disease after mRNA COVID-19 vaccine
por: Magliulo, Daniel, et al.
Publicado: (2021)

Blunted humoral response after mRNA vaccine in patients with haematological malignancies
por: Kamboj, Mini
Publicado: (2021)

SARS-CoV-2 mRNA vaccination and subsequent herpes zoster: Possible immune reconstitution by mRNA vaccination
por: Ota, Mitsuhito
Publicado: (2022)

Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern
por: Kumari, Monika, et al.
Publicado: (2023)

A Bivalent Omicron-Containing Booster Vaccine against Covid-19
por: Chalkias, Spyros, et al.
Publicado: (2022)

Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study
por: Arbel, Ronen, et al.
Publicado: (2023)

Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis
por: Rubbert-Roth, Andrea, et al.
Publicado: (2021)

Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms
por: Heymans, Stephane, et al.
Publicado: (2021)

CS-2034 mRNA vaccine: a new option for COVID-19 infection?
por: Zhang, Ruiqi, et al.
Publicado: (2023)

Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines
por: Ju, Yi, et al.
Publicado: (2022)

Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab
por: Smetanova, Jitka, et al.
Publicado: (2022)

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
por: Springer, David N., et al.
Publicado: (2023)

SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern
por: Ma, Qinhai, et al.
Publicado: (2023)

Durability of immune responses to mRNA booster vaccination against COVID-19
por: Arunachalam, Prabhu S., et al.
Publicado: (2023)

Myocarditis With Ventricular Tachycardia Following Bivalent COVID-19 mRNA Vaccination
por: Yamamoto, Jumpei, et al.
Publicado: (2023)

COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA
por: Krantz, Matthew S, et al.
Publicado: (2022)

Don’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic
por: Morris, Van K., et al.
Publicado: (2022)

Commentary on Demetriou et al. (2018): Methodological and Theoretical Considerations
por: Bäckström, Martin
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_r8jga5md4klnoa9hsbci44l878